ENDRA Life Sciences (NDRA) Net Income towards Common Stockholders (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Net Income towards Common Stockholders for 11 consecutive years, with $159944.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 113.05% year-over-year to $159944.0 in Q2 2026; TTM through Jun 2026 was -$5.9 million, a 6.8% increase from a year earlier, with the FY2025 full-year figure at -$5.6 million, up 38.93% from the prior year.
• Net Income towards Common Stockholders was $159944.0 for Q2 2026 at ENDRA Life Sciences, up from -$1.3 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $159944.0 in Q2 2026 and troughed at -$3.6 million in Q2 2022.
• A 5-year average of -$2.3 million and a median of -$2.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders sank 82.95% in 2025 and jumped 113.05% in 2026, its largest moves.
• Over 5 years, Net Income towards Common Stockholders stood at -$3.3 million in 2022, then jumped by 55.63% to -$1.5 million in 2023, then retreated by 18.69% to -$1.7 million in 2024, then slumped by 82.95% to -$3.2 million in 2025, then surged by 105.05% to $159944.0 in 2026.
• The last three Net Income towards Common Stockholders figures came in at $159944.0 (Q2 2026), -$1.3 million (Q1 2026), and -$3.2 million (Q4 2025), per Business Quant data.